Neurotransmitter Pathway
Summary
Your neurotransmitter profile is not one thing — it's five independent genetic variables operating across four interconnected chemical systems: catecholamines (dopamine, norepinephrine, adrenaline), serotonin, endorphins, and neurotrophic factors. Each system has its own genetics, but they share the same brain, the same stressors, and the same interventions. The compound picture matters because exercise affects ALL of them, stress affects ALL of them, and sleep affects ALL of them — but the degree and direction depends on your specific combination.
Evidence detail
System Overview
Your neurotransmitter profile is not one thing — it's five independent genetic variables operating across four interconnected chemical systems: catecholamines (dopamine, norepinephrine, adrenaline), serotonin, endorphins, and neurotrophic factors. Each system has its own genetics, but they share the same brain, the same stressors, and the same interventions. The compound picture matters because exercise affects ALL of them, stress affects ALL of them, and sleep affects ALL of them — but the degree and direction depends on your specific combination.
What makes the neurotransmitter hub different from looking at each gene individually is multiplicative interaction. A person with slow COMT + low DRD2 density + BDNF Met + OPRM1 G + SLC6A4 GG has a fundamentally different brain chemistry landscape than someone with fast COMT + normal DRD2 + normal BDNF + normal OPRM1 + SLC6A4 AA. Individual entries can't capture how five findings combine to create a unified reward, stress, and resilience profile. This hub does.
The practical consequence: lifestyle interventions are not additive across neurotransmitter genes. The person with compound vulnerability across multiple systems doesn't need five separate interventions — they need an integrated strategy that addresses the shared mechanisms (exercise, stress management, sleep, social connection) with genotype-informed intensity and priority. Conversely, the person with compound advantages has genuine resilience that justifies different guidance.
The caffeine bridge: COMT and the caffeine system (CYP1A2, ADORA2A) are coupled — caffeine triggers catecholamine release, COMT clears catecholamines. See caffeine_response_hub for the compound caffeine picture. This hub focuses on the broader neurotransmitter landscape beyond caffeine.
The methylation bridge: COMT consumes SAM (from the methylation cycle) as its cofactor. MTHFR status directly affects SAM availability and therefore COMT function. BDNF expression is epigenetically regulated by methylation. See methylation_pathway_hub for the methylation-neurotransmitter interaction.
Cross-System Connections
→ System 1: Methylation
COMT is the primary bridge. COMT consumes SAM (from the methylation cycle) for every catecholamine it clears. MTHFR status directly affects SAM availability. BDNF expression is epigenetically regulated by DNA methylation. A methylation-impaired user (MTHFR TT) with neurotransmitter vulnerabilities faces a supply-chain constraint on top of their signalling challenges. See methylation_pathway_hub for compound management.
→ System 2: Caffeine
COMT is again the bridge. Caffeine triggers catecholamine release; COMT clears them. CYP1A2 determines how long caffeine persists; COMT determines how long caffeine's neurological effects persist. ADORA2A affects caffeine anxiety independently. The caffeine-neurotransmitter interaction is strong enough that caffeine guidance should always incorporate COMT status. See caffeine_response_hub.
→ System 4: Vitamin & Mineral Metabolism
B6, folate, and iron are cofactors for neurotransmitter synthesis enzymes (tyrosine hydroxylase, tryptophan hydroxylase, DDC). VDR and FUT2 variants may affect micronutrient availability. When neurotransmitter genetics are compound-vulnerable, ensuring cofactor availability is foundational — you can't optimise signalling if synthesis substrates are missing.
→ System 5: Cardiovascular
Catecholamine-mediated stress (COMT) affects cardiovascular function. Chronic catecholamine excess raises blood pressure and heart rate. ACE/AGT variants (System 5) add independent hypertension risk. The neurotransmitter-cardiovascular interaction is mediated by the sympathetic nervous system.
→ System 7: Sleep & Circadian
All five neurotransmitter genes in this hub affect sleep. COMT: catecholamine clearance during sleep. DRD2: dopamine and melatonin synthesis pathway overlap. BDNF: consolidation during sleep. OPRM1: endorphin-mediated sleep quality. SLC6A4